2009 Annual Meeting | Neuro-oncology Update I: Primary Brain Tumors

Date Sunday 04/26/09

Time 02:15 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Myrna R. Rosenfeld, MD, PhD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with the current recommendations for the treatment of primary brain tumors in adults. This will include identifying the most appropriate diagnostic techniques, how to incorporate prognostic factors into treatment decisions, and current recommendations for systemic therapies. Participants should gain an evidence base for the management of seizures, venous thrombosis, infection during brain tumor treatment, and learn strategies to enhance quality of life for patients with long-term complications and unusual sequelae of tumor therapy.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Resident

Event Timeline
02:15 PM - 03:00 PM		Have We Made Progress in the Treatment of High-Grade Gliomas? Kurt A. Jaeckle, MD, FAAN
03:00 PM - 03:45 PM		A Neurologist's Approach to Meningioma, Medulloblastoma, and Ependymoma Marc Chamberlain, MD
03:45 PM - 04:00 PM		Break
04:00 PM - 04:45 PM		Primary Central Nervous System Lymphoma Update Lauren E. Abrey, MD
04:45 PM - 05:30 PM		Management of Medical Problems in Patients with Brain Tumors Amy A. Pruitt, MD, FAAN
05:30 PM - 06:00 PM		Questions and Answers

Faculty Disclosures
Marc Chamberlain, MD	No disclosure on file
Kurt A. Jaeckle, MD, FAAN	Dr. Jaeckle has stock in Entegrion, Inc.
Amy A. Pruitt, MD, FAAN	Dr. Pruitt has nothing to disclose.
Lauren E. Abrey, MD	No disclosure on file
Myrna R. Rosenfeld, MD, PhD, FAAN	Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. An immediate family member of Dr. Rosenfeld has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ��ɫ��. Dr. Rosenfeld has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Lamson Dugan & Murray LLP. The institution of an immediate family member of Dr. Rosenfeld has received research support from Sage Therapeutics. The institution of an immediate family member of Dr. Rosenfeld has received research support from Edmond J. Safra Foundation. The institution of an immediate family member of Dr. Rosenfeld has received research support from La Caixa Foundation. The institution of an immediate family member of Dr. Rosenfeld has received research support from Spanish Ministry of Health. The institution of an immediate family member of Dr. Rosenfeld has received research support from Department of Health, Government of Catalunya. Dr. Rosenfeld has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Rosenfeld has received intellectual property interests from a discovery or technology relating to health care. Dr. Rosenfeld has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Rosenfeld has received intellectual property interests from a discovery or technology relating to health care. Dr. Rosenfeld has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Rosenfeld has received publishing royalties from a publication relating to health care. Dr. Rosenfeld has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Rosenfeld has received publishing royalties from a publication relating to health care.

��ɫ����

��ɫ����

��ɫ��

��ɫ��